Loading
CT7439 is an experimental pill from Carrick Therapeutics, in phase 1 trials for advanced solid tumours.
CT7439 is a small molecule, oral from Carrick Therapeutics. Blocks the enzymes CDK12 and CDK13 and acts as a molecular glue that breaks down cyclin K, which the company says weakens the cancer cell's repair of damaged DNA at the level of gene transcription. Its phase 1/2 study (NCT06600789) is recruiting people with solid tumours. CDK13 and cyclin K have no target record in OnCo. Whether it works in people has not been established.
Blocks the enzymes CDK12 and CDK13 and acts as a molecular glue that breaks down cyclin K, which the company says weakens the cancer cell's repair of damaged DNA at the level of gene transcription. Connects to CDK12.
1.CT7439 slips into a pocket on CDK12.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CT7439" OR ABSTRACT:"CT7439") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CT7439, not a curated reading list.
Shares Carrick Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/